Low-dose radiotherapy in diffuse large B-cell lymphoma

C. Furlan, V. Canzonieri, M. Spina, M. Michieli, A. Ermacora, R. Maestro, S. Piccinin, R. Bomben, M. Dal Bo, M. Trovo, V. Gattei, U. Tirelli, G. Franchin, P. Bulian

Research output: Contribution to journalArticle

Abstract

Low-dose radiotherapy (LDRT) given in 2 × 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise, very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for palliative radiation. Low-dose radiotherapy was administered on symptomatic areas only. Clinical response was assessed 21 days after LDRT and defined as reduction >50% of maximum diameter of the radiated lesions. Quality of life was scored by the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire. Tumor subtype (germinal center B-cell type versus activated B-cell type) and the presence of TP53 mutations in pathologic specimens of the target lesion were also evaluated. Twenty-three of twenty-five radiated patients were evaluable for response, and 2 died of disease before the visit at 21 days. The overall response rate was 70% (16 of 23 patients), with 7 complete responses and 9 partial responses (mean duration of response, 6 months; range, 1-39 months). Fifteen patients answered to the QLQ-C30 questionnaires, and an improved quality of life was documented in 9 cases. TP53 mutations were detected in 2 of 6 (33%) nonresponders and in none of the responders (P =.12). Germinal center B-cell type responded better than activated B-cell type (response rate was 83% and 29%, respectively, P =.01). These findings indicate that LDRT is effective for palliation in patients with DLBCL. Copyright © 2016 John Wiley & Sons, Ltd.
Original languageEnglish
Pages (from-to)472-479
Number of pages8
JournalHematological Oncology
Volume35
Issue number4
DOIs
Publication statusPublished - 2017

Fingerprint

Lymphoma, Large B-Cell, Diffuse
Radiotherapy
B-Lymphocytes
Germinal Center
Quality of Life
Mutation
Nuclear Family
Lymphoma
Radiation
Neoplasms

Keywords

  • DLBCL
  • low-dose radiotherapy
  • palliation
  • quality of life
  • TP53
  • biological marker
  • protein p53
  • adult
  • aged
  • Article
  • cancer palliative therapy
  • cancer patient
  • cancer radiotherapy
  • clinical article
  • Clinical Target Volume
  • diffuse large B cell lymphoma
  • female
  • follow up
  • gene mutation
  • germinal center
  • human
  • low dose radiotherapy
  • male
  • phase 2 clinical trial
  • physical examination
  • priority journal
  • radiation dose
  • treatment response
  • clinical trial
  • disease free survival
  • middle aged
  • pathology
  • prospective study
  • psychology
  • very elderly
  • Adult
  • Aged
  • Aged, 80 and over
  • Disease-Free Survival
  • Female
  • Humans
  • Lymphoma, Large B-Cell, Diffuse
  • Male
  • Middle Aged
  • Prospective Studies
  • Quality of Life

Cite this

Low-dose radiotherapy in diffuse large B-cell lymphoma. / Furlan, C.; Canzonieri, V.; Spina, M.; Michieli, M.; Ermacora, A.; Maestro, R.; Piccinin, S.; Bomben, R.; Dal Bo, M.; Trovo, M.; Gattei, V.; Tirelli, U.; Franchin, G.; Bulian, P.

In: Hematological Oncology, Vol. 35, No. 4, 2017, p. 472-479.

Research output: Contribution to journalArticle

Furlan, C. ; Canzonieri, V. ; Spina, M. ; Michieli, M. ; Ermacora, A. ; Maestro, R. ; Piccinin, S. ; Bomben, R. ; Dal Bo, M. ; Trovo, M. ; Gattei, V. ; Tirelli, U. ; Franchin, G. ; Bulian, P. / Low-dose radiotherapy in diffuse large B-cell lymphoma. In: Hematological Oncology. 2017 ; Vol. 35, No. 4. pp. 472-479.
@article{4cb718debbd5414487ad38d28e42eb70,
title = "Low-dose radiotherapy in diffuse large B-cell lymphoma",
abstract = "Low-dose radiotherapy (LDRT) given in 2 × 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise, very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for palliative radiation. Low-dose radiotherapy was administered on symptomatic areas only. Clinical response was assessed 21 days after LDRT and defined as reduction >50{\%} of maximum diameter of the radiated lesions. Quality of life was scored by the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire. Tumor subtype (germinal center B-cell type versus activated B-cell type) and the presence of TP53 mutations in pathologic specimens of the target lesion were also evaluated. Twenty-three of twenty-five radiated patients were evaluable for response, and 2 died of disease before the visit at 21 days. The overall response rate was 70{\%} (16 of 23 patients), with 7 complete responses and 9 partial responses (mean duration of response, 6 months; range, 1-39 months). Fifteen patients answered to the QLQ-C30 questionnaires, and an improved quality of life was documented in 9 cases. TP53 mutations were detected in 2 of 6 (33{\%}) nonresponders and in none of the responders (P =.12). Germinal center B-cell type responded better than activated B-cell type (response rate was 83{\%} and 29{\%}, respectively, P =.01). These findings indicate that LDRT is effective for palliation in patients with DLBCL. Copyright {\circledC} 2016 John Wiley & Sons, Ltd.",
keywords = "DLBCL, low-dose radiotherapy, palliation, quality of life, TP53, biological marker, protein p53, adult, aged, Article, cancer palliative therapy, cancer patient, cancer radiotherapy, clinical article, Clinical Target Volume, diffuse large B cell lymphoma, female, follow up, gene mutation, germinal center, human, low dose radiotherapy, male, phase 2 clinical trial, physical examination, priority journal, radiation dose, treatment response, clinical trial, disease free survival, middle aged, pathology, prospective study, psychology, very elderly, Adult, Aged, Aged, 80 and over, Disease-Free Survival, Female, Humans, Lymphoma, Large B-Cell, Diffuse, Male, Middle Aged, Prospective Studies, Quality of Life",
author = "C. Furlan and V. Canzonieri and M. Spina and M. Michieli and A. Ermacora and R. Maestro and S. Piccinin and R. Bomben and {Dal Bo}, M. and M. Trovo and V. Gattei and U. Tirelli and G. Franchin and P. Bulian",
note = "Export Date: 21 February 2018 CODEN: HAOND Correspondence Address: Furlan, C.; Department of Radiation Oncology, Centro di Riferimento Oncologico (CRO), National Cancer InstituteItaly; email: cfurlan@cro.it",
year = "2017",
doi = "10.1002/hon.2368",
language = "English",
volume = "35",
pages = "472--479",
journal = "Hematological Oncology",
issn = "0278-0232",
publisher = "wiley",
number = "4",

}

TY - JOUR

T1 - Low-dose radiotherapy in diffuse large B-cell lymphoma

AU - Furlan, C.

AU - Canzonieri, V.

AU - Spina, M.

AU - Michieli, M.

AU - Ermacora, A.

AU - Maestro, R.

AU - Piccinin, S.

AU - Bomben, R.

AU - Dal Bo, M.

AU - Trovo, M.

AU - Gattei, V.

AU - Tirelli, U.

AU - Franchin, G.

AU - Bulian, P.

N1 - Export Date: 21 February 2018 CODEN: HAOND Correspondence Address: Furlan, C.; Department of Radiation Oncology, Centro di Riferimento Oncologico (CRO), National Cancer InstituteItaly; email: cfurlan@cro.it

PY - 2017

Y1 - 2017

N2 - Low-dose radiotherapy (LDRT) given in 2 × 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise, very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for palliative radiation. Low-dose radiotherapy was administered on symptomatic areas only. Clinical response was assessed 21 days after LDRT and defined as reduction >50% of maximum diameter of the radiated lesions. Quality of life was scored by the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire. Tumor subtype (germinal center B-cell type versus activated B-cell type) and the presence of TP53 mutations in pathologic specimens of the target lesion were also evaluated. Twenty-three of twenty-five radiated patients were evaluable for response, and 2 died of disease before the visit at 21 days. The overall response rate was 70% (16 of 23 patients), with 7 complete responses and 9 partial responses (mean duration of response, 6 months; range, 1-39 months). Fifteen patients answered to the QLQ-C30 questionnaires, and an improved quality of life was documented in 9 cases. TP53 mutations were detected in 2 of 6 (33%) nonresponders and in none of the responders (P =.12). Germinal center B-cell type responded better than activated B-cell type (response rate was 83% and 29%, respectively, P =.01). These findings indicate that LDRT is effective for palliation in patients with DLBCL. Copyright © 2016 John Wiley & Sons, Ltd.

AB - Low-dose radiotherapy (LDRT) given in 2 × 2 Gy is a highly effective and safe treatment for palliation of indolent lymphomas. Otherwise, very little regarding the use of LDRT for diffuse large B-cell lymphoma (DLBCL) has been investigated. We designed a phase 2 trial of LDRT in patients with DLBCL with indication for palliative radiation. Low-dose radiotherapy was administered on symptomatic areas only. Clinical response was assessed 21 days after LDRT and defined as reduction >50% of maximum diameter of the radiated lesions. Quality of life was scored by the European Organisation for Research and Treatment of Cancer QLQ-C30 questionnaire. Tumor subtype (germinal center B-cell type versus activated B-cell type) and the presence of TP53 mutations in pathologic specimens of the target lesion were also evaluated. Twenty-three of twenty-five radiated patients were evaluable for response, and 2 died of disease before the visit at 21 days. The overall response rate was 70% (16 of 23 patients), with 7 complete responses and 9 partial responses (mean duration of response, 6 months; range, 1-39 months). Fifteen patients answered to the QLQ-C30 questionnaires, and an improved quality of life was documented in 9 cases. TP53 mutations were detected in 2 of 6 (33%) nonresponders and in none of the responders (P =.12). Germinal center B-cell type responded better than activated B-cell type (response rate was 83% and 29%, respectively, P =.01). These findings indicate that LDRT is effective for palliation in patients with DLBCL. Copyright © 2016 John Wiley & Sons, Ltd.

KW - DLBCL

KW - low-dose radiotherapy

KW - palliation

KW - quality of life

KW - TP53

KW - biological marker

KW - protein p53

KW - adult

KW - aged

KW - Article

KW - cancer palliative therapy

KW - cancer patient

KW - cancer radiotherapy

KW - clinical article

KW - Clinical Target Volume

KW - diffuse large B cell lymphoma

KW - female

KW - follow up

KW - gene mutation

KW - germinal center

KW - human

KW - low dose radiotherapy

KW - male

KW - phase 2 clinical trial

KW - physical examination

KW - priority journal

KW - radiation dose

KW - treatment response

KW - clinical trial

KW - disease free survival

KW - middle aged

KW - pathology

KW - prospective study

KW - psychology

KW - very elderly

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Lymphoma, Large B-Cell, Diffuse

KW - Male

KW - Middle Aged

KW - Prospective Studies

KW - Quality of Life

U2 - 10.1002/hon.2368

DO - 10.1002/hon.2368

M3 - Article

VL - 35

SP - 472

EP - 479

JO - Hematological Oncology

JF - Hematological Oncology

SN - 0278-0232

IS - 4

ER -